Cocrystal Pharma Valuation
COCP Stock | USD 1.64 0.05 2.96% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Cocrystal Pharma shows a prevailing Real Value of $3.23 per share. The current price of the firm is $1.64. Our model approximates the value of Cocrystal Pharma from analyzing the firm fundamentals such as return on equity of -1.06, and Current Valuation of 11.5 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Cocrystal Pharma's price fluctuation is risky at this time. Calculation of the real value of Cocrystal Pharma is based on 3 months time horizon. Increasing Cocrystal Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cocrystal Pharma's intrinsic value may or may not be the same as its current market price of 1.64, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 1.64 | Real 3.23 | Hype 1.36 | Naive 1.81 |
The intrinsic value of Cocrystal Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cocrystal Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cocrystal Pharma helps investors to forecast how Cocrystal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cocrystal Pharma more accurately as focusing exclusively on Cocrystal Pharma's fundamentals will not take into account other important factors: Cocrystal Pharma Total Value Analysis
Cocrystal Pharma is currently forecasted to have valuation of 11.5 M with market capitalization of 17.19 M, debt of 1.81 M, and cash on hands of 51.03 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cocrystal Pharma fundamentals before making equity appraisal based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
11.5 M | 17.19 M | 1.81 M | 51.03 M |
Cocrystal Pharma Asset Utilization
One of the ways to look at asset utilization of Cocrystal is to check how much profit was generated for every dollar of assets it reports. Cocrystal Pharma shows a negative utilization of assets of -0.54 percent, losing $0.005396 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cocrystal Pharma shows how unproductive it operates for each dollar spent on its assets.Cocrystal Pharma Ownership Allocation
The market capitalization of Cocrystal Pharma is $17.19 Million. Cocrystal Pharma retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Cocrystal Pharma Profitability Analysis
Net Loss for the year was (17.5 M) with loss before overhead, payroll, taxes, and interest of (10.95 M).About Cocrystal Pharma Valuation
The stock valuation mechanism determines Cocrystal Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cocrystal Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cocrystal Pharma. We calculate exposure to Cocrystal Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cocrystal Pharma's related companies.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious andor chronic viral diseases. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp Dohme Corp. to discover and develop proprietary influenza AB antiviral agents a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections and drug discovery collaboration with HitGen and InterX Inc. Cocrystal Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Cocrystal Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cocrystal Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding | 10.2 M |
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.